Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4292-4296

  Ringshausen, Ingo ^a   Feuerstacke, Yvonne ^a   Krainz, Philipp ^a   Hollander, Jürgen Den ^a   Hermann, Ken ^a   Buck, Andreas ^a   Peschel, Christian ^a   Zum Bueschenfelde, Christian Meyer ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CALCIUM ION; CASPOFUNGIN; CD20 ANTIGEN; CD33 ANTIGEN; CD52 ANTIGEN; GEMTUZUMAB OZOGAMICIN; ITRACONAZOLE; MEMBRANE LIPID; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM TRANSPORT; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; LIPID RAFT; LOADING DRUG DOSE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; ECHINOCANDINS; FEMALE; HUMANS; ITRACONAZOLE; JURKAT CELLS; LYMPHOMA; MEMBRANE MICRODOMAINS; MICE; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953150792     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0259     Document Type: Article

References (20)

1. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
2. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999;26:88-96.
3. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. NatMed 2000;6:443-446
4. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-1052
5. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-186 (Pubitemid 27349961)
6. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-2743
7. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387:569-572
8. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
9. Van den Bossche H, Willemsens G, Cools W, Cornelissen F, Lauwers WF, van Cutsem JM. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980;17:922-928
10. Ferch U, zum Buschenfelde CM, Gewies A, et al. MALT1 directs B cell receptor-induced canonical nuclear factor-κB signaling selectively to the c-Rel subunit. Nat Immunol 2007;8:984-991
11. Meyer zum Buschenfelde C, Feuerstacke Y, Gotze KS, Scholze K, Peschel C. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res 2008;68:5414-5422
12. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139:439-446
13. MacCallum DM, Odds FC. Efficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains. J Antimicrob Chemother 2002;50:225-229
14. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 1999;190:1549-1560
15. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity 1998;8:723-732
16. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-279
17. Meyer zum Bueschenfelde CO, Unternaehrer J, Mellman I, Bottomly K. Regulated recruitment of MHC class II and costimulatory molecules to lipid rafts in dendritic cells. J Immunol 2004;173:6119-6124
18. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27:3398-3409
19. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
20. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412-417